UCB SA (OTCMKTS:UCBJF) Short Interest Up 20.8% in March

UCB SA (OTCMKTS:UCBJF - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 15th, there was short interest totalling 481,000 shares, a growth of 20.8% from the February 28th total of 398,200 shares. Approximately 0.3% of the company's shares are short sold. Based on an average daily trading volume, of 3,100 shares, the short-interest ratio is presently 155.2 days.UCB Stock PerformanceUCBJF opened at $172.33 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The stock's 50 day moving average price is $190.96 and its 200-day moving average price is $186.42. UCB has a one year low of $123.00 and a one year high of $209.66. About UCB (Get Free Report)UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.Featured StoriesFive stocks we like better than UCBLearn Technical Analysis Skills to Master the Stock MarketD-Wave: Multiple Use Cases Emerge Following Quantum SupremacyInsider Selling Explained: Can it Inform Your Investing Choices?Amazon Falls Back to a Key Support Line: Here's How to Play ItBest Stocks Under $10.00 Buffett Trims Equities, But Still Keeps Buying This Stock This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in UCB Right Now?Before you consider UCB, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UCB wasn't on the list.While UCB currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here